Plant Extract Composition for Enteroendocrine Cell Stimulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical and food compositions aimed at treating diabetes, obesity, heart diseases, and other metabolic disorders often have significant side effects and are not effective in stimulating enteroendocrine cells safely.
Innovation Solution
A composition containing extracts from Oldenlandia brachypoda, Spergularia marina, Disporum smilacinum, and Geum aleppicum, which stimulate enteroendocrine cells to secrete gut hormones and neuropeptides like GLP-1, CCK, and 5-HT, thereby treating diabetes, obesity, heart diseases, and improving digestion and malabsorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmaceutical compositions are used to treat diabetes and obesity, then therapeutic effects are achieved, but significant side effects occur
Solution Approach 1:
The patent changes the chemical composition parameters by using natural plant extracts (Oldenlandia brachypoda, Spergularia marina, Disporum smilacinum, Persicaria posumbu, Geum aleppicum) instead of conventional pharmaceutical compounds. These plant extracts contain bioactive compounds that can stimulate enteroendocrine cells to secrete GLP-1 and other gut hormones, achieving therapeutic effects for diabetes and obesity with fewer side effects.
Solution Approach 2:
The patent introduces plant extract components as intermediary substances that mediate between the administration route and the target enteroendocrine cells. These intermediaries (plant-derived compounds) activate TGR5 receptors and stimulate endogenous GLP-1 secretion, providing a gentler alternative to direct pharmaceutical intervention while maintaining therapeutic efficacy.
2Reliability
If current treatments for metabolic disorders are administered, then disease symptoms are addressed, but effectiveness in stimulating enteroendocrine cells is insufficient
Solution Approach 1:
The patent optimizes the chemical parameters of the treatment by using specific plant extracts rich in compounds that can penetrate and activate enteroendocrine cells. The plant extracts contain phenolic compounds, flavonoids, and other bioactive molecules that effectively stimulate GLP-1 secretion, enhancing the productivity of enteroendocrine cell activation compared to conventional treatments.
Solution Approach 2:
The patent employs composite plant extract formulations combining multiple plant sources (Oldenlandia brachypoda, Spergularia marina, Disporum smilacinum, Persicaria posumbu, Geum aleppicum). This composite approach creates synergistic effects where different plant compounds work together to enhance enteroendocrine cell stimulation and GLP-1 secretion, improving overall effectiveness.
Data Source
AI summary
The present disclosure relates to a pharmaceutical composition or a food composition which has excellent activity of stimulating enteroendocrine cells while being safe with few side effects. The composition contains one or more of an Oldenlandia brachypoda extract, a Spergularia marina extract, a Disporum smilacinum extract, a Persicaria posumbu extract and a Geum aleppicum extract as an active ingredient. The composition of the present disclosure can be usefully used as a pharmaceutical composition or a food composition for preventing, improving or treating diabetes mellitus, improving or treating heart diseases, improving or treating arteriosclerosis, improving or treating digestive disorders and malabsorption, preventing or treating obesity or suppressing appetite, protecting nerves, treating or improving liver diseases, and so forth. In addition, the composition of the present disclosure can promote the secretion of GLP-1, CCK or 5-HT, affect the activation of hTGR5 and act as TRP, TRPA1, G protein and PLCĪ²2 agonists.